0 0 0 0 0.000147960830732828 -0.000775045733347643 0.00142580436887973 0.00859517916711501
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron's push to extend its oncology footprint and expand into genetic medicines, potentially broadening its future sources of revenue beyond current flagship products. Next, we'll explore how Lynozyfic's early multiple myeloma data could reshape Regeneron's investment narrative and long-term growth profile. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Regeneron, you have to believe its core eye and immunology franchises can hold up while a broad pipeline, including oncology and genetic medicines, matures into meaningful revenue. The latest Lynozyfic data and Tessera “Gene Writing” deal s [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Lynozyfic™ (linvoseltamab), advanced a broad early-stage program in newly diagnosed patients, and entered a global collaboration with Tessera Therapeutics to develop TSRA-196, an in vivo “Gene Writing” candidate for alpha-1 antitrypsin deficiency. These updates highlight Regeneron's push to extend its oncology footprint and expand into genetic medicines, potentially broadening its future sources of revenue beyond current flagship products. Next, we'll explore how Lynozyfic's early multiple myeloma data could reshape Regeneron's investment narrative and long-term growth profile. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Regeneron, you have to believe its core eye and immunology franchises can hold up while a broad pipeline, including oncology and genetic medicines, matures into meaningful revenue. The latest Lynozyfic data and Tessera “Gene Writing” deal s [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS